Citations

Clear

69 citation(s) found for "Feagan, Brian".

Recommendations for Standardizing MRI-based Evaluation of Perianal Fistulizing Disease Activity in Pediatric Crohn’s Disease Clinical Trials
Crowley, Eileen , Ma, Christopher , Guizzetti, Leonard, Lewindon, Peter , Gee, Michael S. , Hyams, Jeffrey S. , Rosen, Michael J. , Allmen, Daniel von, Overstraeten, Anthony de Buck van , Shackelton, Lisa M. , Rémillard, Julie, Schleicher, Lauren S., Rimola, Jordi , Taylor, Stuart A. , Church, Peter , Feagan, Brian G. , Jairath, Vipul , Jairath, Vipul , Jairath, Vipul , Hyams, Jeffrey S , Shackelton, Lisa M , Rimola, Jordi , Ma, C , Jairath, V , Jairath, V , Jairath, Vipul , Zou, Guangyong , Gee, Michael Stanley , Dillman, Jonathan R , Fletcher, Joel G. , Griffiths, Anne Marie , Greer, Mary‐Louise C.

Mayo Clinic

Inflammatory Bowel Diseases | July 31, 2023 | Volume: 30 | Issue: 3 | Pages: 357-369

10.1093/ibd/izad134 | PMID 37524088 Get It

Abstract Background Perianal fistulas and abscesses occur commonly as complications of pediatric Crohn’s disease (CD). A validated imaging assessment tool for quantification of perianal disease severity and activity is needed to evaluate treatment response. We aimed to identify magnetic resonance imaging (MRI)-based measures of perianal fistulizing disease activity and study design features appropriate for pediatric patients. Methods Seventy-nine statements relevant to MRI-based assessment of pediatric perianal fistulizing CD activity and clinical trial design were generated from literature review and expert opinion. Statement appropriateness was rated by a panel (N = 15) of gastroenterologists, radiologists, and surgeons using modified RAND/University of California Los Angeles appropriateness methodology. Results The modified Van Assche Index (mVAI) and the Magnetic Resonance Novel Index for Fistula Imaging in CD (MAGNIFI-CD) were considered appropriate instruments for use in pediatric perianal fistulizing disease clinical trials. Although there was concern regarding the use of intravascular contrast material in pediatric patients, its use in clinical trials was considered appropriate. A clinically evident fistula tract and radiologic disease defined as at least 1 fistula or abscess on pelvic MRI were considered appropriate trial inclusion criteria. A coprimary clinical and radiologic end point and inclusion of a patient-reported outcome were also considered appropriate. Conclusion Outcomes of treatment of perianal fistulizing disease in children must include MRI. Existing multi-item measures, specifically the mVAI and MAGNIFI-CD, can be adapted and used for children. Further research to assess the operating properties of the indices when used in a pediatric patient population is ongoing.
P304 Impact of mirikizumab on histologic measures of intestinal inflammation in a phase 2 study of patients with moderate-severe crohn’s disease
Pai, Rish K. , Reinisch, Walter , Feagan, Brian G. , Agada, Noah , Pollack, Paul, Chan, Lai Shan, Protić, Marijana , Dhesi, Endip , Hertogh, Gert D. , Reinisch, Walter , Harpaz, Noam , Magro, Fernando

Mayo Clinic

Poster presentations | June 18, 2023 | Volume: No volume available | Issue: No issue available | Pages: A210.1-A210

10.1136/gutjnl-2023-bsg.370 Get It

Impact of mirikizumab therapy on histologic measures of intestinal inflammation in a Phase 2 study of patients with moderately to severely active Crohn’s disease
Pai, Rish K. , Reinisch, Walter , Feagan, Brian G. , Agada, Noah , Pollack, P, Protić, Marijana , Hertogh, Gert D. , Reinisch, Walter , Harpaz, Noam , Chan, L., Magro, Fernando

Mayo Clinic

Zeitschrift für Gastroenterologie | June 13, 2023 | Volume: 61 | Issue: 05 | Pages: e183-e184

10.1055/s-0043-1769022 Get It

Rapid and Sustained Symptom Relief in Patients With Ulcerative Colitis Treated With Filgotinib: Data From the Phase 2b/3 SELECTION Trial
Ferrante, Marc , Feagan, Brian G. , Hibi∥, Toshifumi , Sandborn, William J. , Ritter, Timothy E., Loftus, Edward V. , Rogler, Gerhard , Oortwijn, Alessandra , Yun, Chohee , Brun, Franck‐Olivier Le , Dinoso, Jason B., Hsieh, Jeremy, Vermeire, Séverine , Loftus, Edward V , Vermeire, Séverine , Danese, Silvio , Peyrin‐Biroulet, Laurent , Schreiber, Stefan

Mayo Clinic

American Journal of Gastroenterology | September 16, 2022 | Volume: 118 | Issue: 1 | Pages: 138-147

10.14309/ajg.0000000000001979 | PMID 36113491 Get It

INTRODUCTION: Patients with ulcerative colitis (UC) regard rapid onset of action among the most important aspects of their treatment. We used the partial Mayo Clinic Score (pMCS) and component patient-reported subscores to assess the rapidity and sustainability of response to filgotinib, a once-daily, oral Janus kinase 1 preferential inhibitor, in adults with moderately to severely active UC in the phase 2b/3 SELECTION trial. The association between early symptomatic improvements and health-related quality of life (HRQoL) outcomes was also assessed. METHODS: In these post hoc analyses of the double-blinded, randomized, placebo-controlled 58-week SELECTION trial (NCT02914522), rectal bleeding and stool frequency diary data on days 1–15 and pMCS remission and response at multiple time points including weeks 10 and 58 were evaluated. HRQoL was assessed using the Inflammatory Bowel Disease Questionnaire at weeks 10 and 58. RESULTS: Filgotinib 200 mg relative to placebo improved rectal bleeding and stool frequency within 7 days ( P < 0.05). By week 2, greater proportions of filgotinib 200 mg-treated patients than placebo-treated patients achieved pMCS remission (biologic-naive, 15.1% vs 8.0%, P = 0.0410; biologic-experienced, 10.3% vs 4.2%, P = 0.0274). A similar treatment effect was observed at week 58 ( P < 0.0001). Day 7 rectal bleeding and stool frequency subscores were associated with the Mayo Clinic Score response at weeks 10 and 58. Patients in pMCS remission at weeks 10 and 58 had greater improvements in the Inflammatory Bowel Disease Questionnaire score than those not in pMCS remission. DISCUSSION: Filgotinib 200 mg daily resulted in rapid and sustained improvements in both UC symptoms and HRQoL.
Corticosteroid-Sparing Effects of Filgotinib in Moderately to Severely Active Ulcerative Colitis: Data from the Phase 2b/3 SELECTION Study
Loftus, Edward V. , Vermeire, Séverine , Feagan, Brian G. , Brun, Franck‐Olivier Le , Oortwijn, Alessandra , Moerch, Ulrik, Sandborn, William J. , Hibi∥, Toshifumi , Loftus, Edward V , Vermeire, Séverine , Moerch, Ulrik

Mayo Clinic

Journal of Crohn's and Colitis | August 24, 2022 | Volume: 17 | Issue: 2 | Pages: 211-220

10.1093/ecco-jcc/jjac122 | PMID 36006011 Get It

Abstract Background and Aims Corticosteroid-free remission is an important treatment goal for patients with ulcerative colitis [UC]. The corticosteroid-sparing effects of filgotinib, an oral, Janus kinase 1 preferential inhibitor, were assessed in SELECTION, a placebo-controlled, phase 2b/3 trial in moderately to severely active UC. Methods These post hoc analyses assessed 1-, 3-, 6-, and 8-month rates of corticosteroid-free clinical remission at Week 58 and change in median daily prednisone-equivalent dose over time. A matching-adjusted indirect comparison [MAIC] of maintenance studies assessed corticosteroid-free remission with filgotinib 200 mg, intravenous vedolizumab, subcutaneous vedolizumab, and oral tofacitinib. Results The Maintenance Study full analysis set included 199 patients receiving filgotinib 200 mg and 98 receiving placebo. Among patients receiving corticosteroids at Maintenance Study baseline, at Week 58, 30.4%, 29.3%, 27.2%, and 21.7% receiving filgotinib had been in corticosteroid-free remission for ≥1, ≥3, ≥6, or ≥8 months, respectively, versus 6.4% receiving placebo across thresholds [p &lt;0.05]. Median daily prednisone-equivalent dose decreased from 17.5 mg/day to 10.0 mg/day with filgotinib treatment during the Maintenance Study. Based upon the MAIC, filgotinib was associated with greater likelihood of corticosteroid-free clinical remission versus intravenous vedolizumab (odds ratio [OR], 15.2; 95% confidence interval [CI], 1.6–139.9; p &lt;0.05]) and similar odds to subcutaneous vedolizumab [OR, 3.8; CI, 0.2–63.8; p = 0.36] in biologic-naïve patients, and similar odds to tofacitinib overall [OR, 2.0; 0.4–9.1; p = 0.39]. Conclusions Filgotinib 200 mg demonstrated corticosteroid-sparing effects and maintained corticosteroid-free clinical remission in patients with UC. MAIC results should be interpreted cautiously given the large CIs and differences in study design and patient populations. [ClinicalTrials.gov: NCT02914522].
Development and Validation of a Digital Analysis Method to Quantify CD3-immunostained T Lymphocytes in Whole Slide Images of Crohn’s Disease Biopsies
Lefèvre, Pavine, Guizzetti, Leonardo , Zou, Guangyong , Viegen, Tanja van, McFarlane, Stefanie C., Shackelton, Lisa M. , Feagan, Brian G. , Jairath, Vipul , Pai, Rish K. , Jairath, Vipul , Jairath, Vipul , Guizzetti, L , Jairath, V , Jairath, V , Jairath, Vipul , Zou, Guangyong , McKee, Trevor D. , Casteele, Niels Vande

Mayo Clinic

Applied Immunohistochemistry & Molecular Morphology | May 19, 2022 | Volume: 30 | Issue: 7 | Pages: 486-492

10.1097/pai.0000000000001035 | PMID 35587994 Get It

The T-lymphocyte–mediated inflammation in Crohn's disease can be assessed by quantifying CD3-positive T-lymphocyte counts in colonic sections. We developed and validated a process to reliably quantify immunohistochemical marker-positive cells in a high-throughput setting using whole slide images (WSIs) of CD3-immunostained colonic and ileal tissue sections. In regions of interest (ROIs) and/or whole tissue sections of 40 WSIs from 36 patients with Crohn's disease, CD3-positive cells were quantified by an expert gastrointestinal pathologist (gold standard) and by image analysis algorithms developed with software from 3 independent vendors. Semiautomated quantification of CD3-positive cell counts estimated in 1 ROI per section were accurate when compared with manual analysis (Pearson correlation coefficient, 0.877 to 0.925). Biological variability was acceptable in digitally determined CD3-positive cell measures between 2 to 5 ROIs annotated on the same tissue section (coefficient of variation <25%). Results from computer-aided analysis of CD3-positive T lymphocytes in a whole tissue section and the average of results from 2 to 5 ROIs per tissue section lacked reliability (overestimation or underestimation and systematic bias), suggesting that absolute quantification of CD3-positive T lymphocytes in a whole tissue section may be more accurate. Semiautomated image analysis in WSIs demonstrated reproducible CD3-positive cell measures across 3 independent algorithms. A computer-aided digital image analysis method was developed and validated to quantify CD3-positive T lymphocytes in colonic and ileal biopsy sections from patients with Crohn's disease. Results support consideration of this digital analysis method for use in future Crohn's disease clinical studies.
Reliability of histologic assessment for NAFLD and development of an expanded NAFLD activity score
Pai, Rish K. , Hogan, Malcolm , Zou, Guangyong , Adeyi, Oyedele , Anstee, Quentin M. , Aqel, Bashar , Behling, Cynthia , Carey, Elizabeth J. , Feagan, Brian G. , McFarlane, Stefanie C., Noureddin, Mazen , Younossi, Zobair M. , Loomba, Rohit , Ratziu, Vlad , Anstee, Quentin M , Corey, Kathleen , Ma, C , Ratziu, Vlad , Loomba, Rohit , Ratziu, Vlad , Adeyi, Oyedele , Zou, Guangyong , Jairath, Vipul , Aqel, Bashar A. , Clouston, Andrew Donald , Corey, Kathleen E. , Kleiner, David Erwin , Ma, Christopher , Valasek, Mark A. , Harrison, Stephen A.

Mayo Clinic

Hepatology | March 25, 2022 | Volume: 76 | Issue: 4 | Pages: 1150-1163

10.1002/hep.32475 | PMID 35332569 Get It

Abstract Background and Aims The NASH Clinical Research Network histologic scoring system, the gold‐standard NASH histology assessment for clinical trials, has demonstrated intrarater and interrater variability. An expert panel in a previous systematic Research and Development/University of California Los Angeles (RAND/UCLA) study determined that existing histologic scoring systems do not fully capture NASH disease activity and fibrosis, and standardized definitions of histologic features are needed. We evaluated the reliability of existing and alternate histologic measures and their correlations with a disease activity visual analog scale to propose optimal components for an expanded NAFLD activity score (NAS). Approach and Results Four liver pathologists who were involved in the prior RAND/UCLA study underwent standardized training and multiple discussions with the goal of improving agreement. They were blinded to clinical information and scored histologic measures twice, ≥2 weeks apart, for 40 liver biopsies representing the full spectrum of NAFLD. Index intraclass correlation coefficient (ICC) estimates demonstrated intrarater (0.80–0.85) and interrater (0.60–0.72) reliability. Hepatocyte ballooning items had similar interrater ICCs (0.68–0.79), including those extending scores from 0–2 to 0–4. Steatosis measures (interrater ICCs, 0.72–0.80) correlated poorly with disease activity. Correlations with disease activity were largest for hepatocyte ballooning and Mallory‐Denk bodies (MDBs), with both used to develop the expanded NAS (intrarater ICC, 0.90; interrater ICC, 0.80). Fibrosis measures had ICCs of 0.70–0.87. Conclusions After extensive preparation among a group of experienced pathologists, we demonstrated improved reliability of multiple existing histologic NAFLD indices and fibrosis staging systems. Hepatocyte ballooning and MDBs most strongly correlated with disease activity and were used for the expanded NAS. Further validation including evaluation of responsiveness is required.
Recommendations for standardizing biopsy acquisition and histological assessment of immune checkpoint inhibitor-associated colitis
Ma, Christopher , Pai, Rish K. , Krell, Jonathan , Guizzetti, Leonardo , McFarlane, Stefanie C., MacDonald, John K, Choi, Won‐Tak , Feakins, Roger , Kirsch, Richard , Lauwers, Gregory Y. , Pai, Reetesh K. , Rosty, Christophe , Srivastava, Amitabh , Walsh, Joanna C. , Feagan, Brian G. , Ma, C , Guizzetti, L , Rosty, Christophe , Srivastava, Amitabh , Schaeffer, David F. , Jairath, Vipul

Mayo Clinic

Journal for ImmunoTherapy of Cancer | March 16, 2022 | Volume: 10 | Issue: 3 | Pages: e004560

10.1136/jitc-2022-004560 | PMID 35296560 Get It

Immune checkpoint inhibitor-associated colitis (ICIC) affects approximately 15% of cancer patients treated with immunotherapy. Although histological evaluation is potentially valuable for both the diagnosis of ICIC and evaluation of disease activity, use in clinical practice is heterogeneous. We aimed to develop expert recommendations to standardize histological assessment of disease activity in patients with ICIC. Using the modified Research and Development/University of California Los Angeles (RAND/UCLA) appropriateness methodology, an international panel of 11 pathologists rated the appropriateness of 99 statements on a 9-point Likert scale during two rounds of anonymous voting. Results were discussed between rounds using moderated videoconferences. There are currently no disease-specific instruments for assessing histological features of ICIC. The panel considered that colonoscopy with at least three biopsies per segment from a total of at least five segments, including both endoscopically normal and inflamed areas, was appropriate for tissue acquisition. They agreed that biopsies should be oriented such that the long axis of the colonic crypts is visualized and should be stained with hematoxylin and eosin. Histological items that the panel voted were appropriate to evaluate in ICIC included the degree of structural/architectural change, chronic inflammatory infiltrate, lamina propria and intraepithelial neutrophils, crypt abscesses and destruction, erosions/ulcerations, apoptosis, surface intraepithelial lymphocytosis, and subepithelial collagen thickness. The appropriateness of routine immunohistochemistry was uncertain. These expert recommendations will help standardize assessment of histological activity in patients with ICIC. The panel also identified the development and validation of an ICIC-specific histological index as a research priority.
Editorial: protecting hypoxia‐inducible factor 1a and gut integrity with GB004—a promising therapeutic approach for ulcerative colitis? Authors' reply
Levesque, Barrett G., Feagan, Brian G. , Jucov, Alina , Bhandari, Bal Raj, Pai, Rish K. , Meadows, Kristen Taylor, Bruey, Jean‐Marie, Olson, Allan, Osterhout, Robin , Biene, Courtney Van, Ford, Julia, Aranda, Richard, Raghupathi, Kartik, Sandborn, William J. , Danese, Silvio , Sandborn, W J , Danese, Silvio , Kirby, Brian J. , Osterhout, Robin E.

Mayo Clinic

Alimentary Pharmacology & Therapeutics | March 4, 2022 | Volume: 55 | Issue: 6 | Pages: 735-736

10.1111/apt.16795 | PMID 35245951 Get It

LINKED CONTENTThis article is linked to Danese et al papers. To view these articles, visit https://doi.org/10.1111/apt.16753 and https://doi.org/10.1111/apt.16761
DOP87 Association of histologic measurement with endoscopic outcomes after one year of treatment with mirikizumab in patients with moderate to severe Crohn’s Disease
Protić, Marijana , Chan, Lai Shan, Pollack, P, Feagan, Brian G. , Pai, Rish K. , Reinisch, Walter , Magro, Fernando , Hertogh, Gert D. , Harpaz, Noam , Reinisch, Walter

Mayo Clinic

Journal of Crohn's and Colitis | January 21, 2022 | Volume: 16 | Issue: Supplement_1 | Pages: i129-i130

10.1093/ecco-jcc/jjab232.126 Get It

Abstract Background There is a scarcity of data regarding the role of histopathology evaluation in Crohn’s disease (CD) and how it relates to endoscopy. Mirikizumab (miri) has shown efficacy in Ph2 studies in CD and ulcerative colitis (UC). Here we explore the agreement of histologic response and remission with endoscopic outcomes after 12 and 52 weeks of treatment with miri in a phase 2 randomized clinical trial (SERENTIY; NCT02891226) in patients with moderate-to-severe CD. Methods Patients were randomized 2:1:1:2 across 4 treatment arms (PBO, 200, 600, 1000mg miri) administered intravenously (IV) every four weeks (Q4W) at Weeks 0, 4, and 8. Those who received miri and achieved ≥1 point improvement from baseline (BL) at W12 in Simple Endoscopic Score for Crohn’s Disease (SES-CD) were re-randomized 1:1 into double-blind maintenance to continue their IV dose assignment Q4W (IV/IV) or to 300mg miri SC Q4W (IV/SC); due to small numbers, maintenance IV arms were pooled for analysis. W12 non-improvers and all induction PBO patients received 1000mg miri Q4W from W12 through W52. Biopsies were obtained during endoscopy at W0, 12 and 52 from the edge of the ulcers and the most inflamed mucosa in terminal ileum and 4 colonic segments (ascending, transverse, descending, rectum; N=10/patient, 2 per location with the more severe score used), and scored by central readers blind to study treatment, timepoint, and response status. Histologic endpoints were defined post-hoc but prior to performing the analyses (see Table footnotes for definitions). Cohen’s Kappa Coefficient was used to evaluate the degree of agreement of two measures. Results At Week 12, there was an overall 69.6% agreement in histologic and endoscopic response, and 84.2% agreement between histologic remission and endoscopic remission (Table 1). After 52 weeks of miri treatment, the agreement between histologic and endoscopic response was 61.9%, while the agreement between histologic and endoscopic remission was 70.6% (Table 2). Interestingly, in every comparison, the percentage of patients achieving the histologic outcome but not the endoscopic outcome was greater than that of patients achieving the endoscopic outcome but not the histologic outcome. Conclusion Histologic and endoscopic outcomes demonstrated fair association after both 12 and 52 weeks of miri treatment. Histologic endpoints, despite the stringent criteria, appear to be more sensitive to change than endoscopic endpoints. However, variability of biopsy sampling may be an additional factor contributing to these differences.